CN101588798A - 用于治疗眼部病症的pai-1结合分子 - Google Patents

用于治疗眼部病症的pai-1结合分子 Download PDF

Info

Publication number
CN101588798A
CN101588798A CNA2007800407976A CN200780040797A CN101588798A CN 101588798 A CN101588798 A CN 101588798A CN A2007800407976 A CNA2007800407976 A CN A2007800407976A CN 200780040797 A CN200780040797 A CN 200780040797A CN 101588798 A CN101588798 A CN 101588798A
Authority
CN
China
Prior art keywords
pai
volume
weight
composition
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800407976A
Other languages
English (en)
Chinese (zh)
Inventor
D·弗里诺
彭玉豪
A·克拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Manufacturing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Manufacturing Ltd filed Critical Alcon Manufacturing Ltd
Publication of CN101588798A publication Critical patent/CN101588798A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800407976A 2006-10-31 2007-10-31 用于治疗眼部病症的pai-1结合分子 Pending CN101588798A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86371506P 2006-10-31 2006-10-31
US60/863,715 2006-10-31

Publications (1)

Publication Number Publication Date
CN101588798A true CN101588798A (zh) 2009-11-25

Family

ID=39345074

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800407976A Pending CN101588798A (zh) 2006-10-31 2007-10-31 用于治疗眼部病症的pai-1结合分子

Country Status (11)

Country Link
US (2) US20080107644A1 (enExample)
EP (1) EP2077829A2 (enExample)
JP (1) JP2010508306A (enExample)
KR (1) KR20090082401A (enExample)
CN (1) CN101588798A (enExample)
AU (1) AU2007313684A1 (enExample)
CA (1) CA2666316A1 (enExample)
MX (1) MX2009004792A (enExample)
RU (1) RU2465898C2 (enExample)
WO (1) WO2008055205A2 (enExample)
ZA (1) ZA200902453B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103959068A (zh) * 2011-11-15 2014-07-30 国立大学法人浜松医科大学 基于纤溶酶原激活物抑制剂－1的流产、早产治疗药

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158897A1 (en) * 2006-10-31 2010-06-24 Alcon Research, Ltd. Pai-1 modulators for the treatment of ocular disorders
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
US10946076B2 (en) 2013-02-13 2021-03-16 The Research Foundation For The State University Of New York Glaucoma treatment
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024121A1 (fr) * 1992-05-22 1993-12-09 Senju Pharmaceutical Co., Ltd. Medicament pour le glaucome
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
WO2000035439A1 (en) * 1998-12-11 2000-06-22 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy
CA2358400C (en) * 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
CA2476761A1 (en) * 2002-02-19 2003-08-28 Vanderbilt University Therapeutic methods employing pai-1 inhibitors and transgenic non-human animal for screening candidate pai-1 inhibitors
KR20040104566A (ko) * 2002-04-30 2004-12-10 알콘, 인코퍼레이티드 안압 저하 및 녹내장성 망막병증/시신경병증 치료를 위한특유의 수단으로서의 결합 조직 성장 인자 (ｃｔｇｆ)의활성 및/또는 발현 조절, 저해, 또는 변조제

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103959068A (zh) * 2011-11-15 2014-07-30 国立大学法人浜松医科大学 基于纤溶酶原激活物抑制剂－1的流产、早产治疗药
CN103959068B (zh) * 2011-11-15 2016-04-06 国立大学法人浜松医科大学 基于纤溶酶原激活物抑制剂－1的流产、早产治疗药
US9448234B2 (en) 2011-11-15 2016-09-20 National University Corporation Hamamatsu University School Of Medicine Therapeutic agent for preterm delivery or abortion using plasminogen activator inhibitor-1

Also Published As

Publication number Publication date
EP2077829A2 (en) 2009-07-15
CA2666316A1 (en) 2008-05-08
ZA200902453B (en) 2010-07-28
MX2009004792A (es) 2009-05-21
WO2008055205A2 (en) 2008-05-08
JP2010508306A (ja) 2010-03-18
WO2008055205A3 (en) 2008-07-17
US20080107644A1 (en) 2008-05-08
AU2007313684A1 (en) 2008-05-08
KR20090082401A (ko) 2009-07-30
US20100260784A1 (en) 2010-10-14
RU2465898C2 (ru) 2012-11-10
RU2009120545A (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
RU2297243C2 (ru) Ингибиторы киназы-3 гликогенсинтазы (gsk-3) для лечения глаукомы
Cheng et al. Angiotensin II attenuates renal cortical cyclooxygenase-2 expression
Barnett et al. Pharmacologic and genetic manipulation of MMP-2 and-9 affects retinal neovascularization in rodent models of OIR
US20140073611A1 (en) Methods for drug screen using zebrafish model and the compounds screened therefrom
Wang et al. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes
CN101588798A (zh) 用于治疗眼部病症的pai-1结合分子
WO2004069181A2 (en) Composition for the treatment of intraocular pressure
US20110105574A1 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
Wu et al. Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells
Sharif et al. Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule
Ellis Guanylate cyclase activators, cell volume changes and IOP reduction
JP2005538061A (ja) 新規ｍａｘｉ−ｋチャネルブロッカー、その使用方法および製造方法
US20110301125A1 (en) Method for Treating Macular Degeneration
Pumphrey et al. Evaluation of matrix metalloproteinases and tissue inhibitors of metalloproteinases in aqueous humor of dogs with versus without naturally occurring primary angle-closure glaucoma
US20090181896A1 (en) Use of Natriuretic Peptide Receptor Antagonists to Treat Ocular, Otic and Nasal Edemetous Conditions
Zarnowski et al. Content of kynurenic acid and activity of kynurenine aminotransferases in mammalian eyes
Kaplan-Messas et al. Ocular hypotensive effects of cholinergic and adrenergic drugs may be influenced by prostaglandins E2 in the human and rabbit eye
US20100158897A1 (en) Pai-1 modulators for the treatment of ocular disorders
JPWO2008090742A1 (ja) 眼疾患モデル用非ヒト動物
US20080187572A1 (en) Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation
EP3096780A1 (en) Abl1 inhibitor for treating and preventing ocular neovascularisation
US6534475B1 (en) Use of TIMP-3 inducers of TIMP-3 expression, and TIMP-3 mimetics to treat ocular neovascularization
US20120101160A1 (en) Use of chemical chaperones to treat glaucoma caused by misfolded or misprocessed proteins
WO2008103301A2 (en) Treatment of the eye using macrophages and/or agents able to affect blood vessel morphology
US9872863B2 (en) Targeting primary cilia to treat glaucoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20091125